Articles

Combinations of novel immunotherapy agents provide benefits over standard-of-care therapy in NSCLC and malignant pleural mesothelioma. Read More ›

Year in Review

First-Line Nivolumab plus Ipilimumab Combined with 2 Cycles of Chemotherapy in Patients with Stage IV/Recurrent NSCLC: 2-Year Update of CheckMate-9LA

Dual IO 2021 - Year in Review

Nivolumab plus ipilimumab combined with 2 cycles of chemotherapy for the treatment of advanced NSCLC demonstrates durable efficacy compared with 4 cycles of chemotherapy alone in a 2-year follow-up study. Read More ›

Year in Review

Four-Year Follow-Up Data for First-Line Nivolumab Combined with Ipilimumab in NSCLC: CheckMate-227

Dual IO 2021 - Year in Review

After more than 4 years of follow-up, patients with advanced NSCLC treated with nivolumab plus ipilimumab maintained overall survival rates. Read More ›

Year in Review

Durvalumab Alone or in Combination with Tremelimumab and Chemotherapy versus Chemotherapy Alone as First-Line Treatment for Metastatic NSCLC: POSEIDON Study

Dual IO 2021 - Year in Review

Durvalumab plus standard-of-care chemotherapy and durvalumab with tremelimumab plus standard-of-care chemotherapy were both associated with better progression-free survival compared with standard-of-care chemotherapy alone in the treatment of metastatic NSCLC. Read More ›

Videos Year in Review

Benefits of Dual Immune Checkpoint Inhibitor Therapy in Metastatic NSCLC

By Mark A. Socinski, MD

Dual IO 2021 - Year in Review

Dual immune checkpoint inhibitor therapy provides significant and durable survival benefits over chemotherapy as first-line treatment in metastatic NSCLC. Read More ›

Combination Therapy for Patients with CLL

Updated findings from a study of ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia (CLL), focusing specifically on the results of minimal residual disease testing. Read More ›

AVID200 Improves Platelet Counts in Patients with Myelofibrosis After Discontinuation of Ruxolitinib

ASH 2021 – Myelofibrosis: Wrap-up

Previous studies have established a role for TGFβ in promoting development and progression of myelofibrosis. Evidence suggests AVID200, a TGFβ1/3 inhibitor, may modulate TGFβ signaling mechanisms associated with myelofibrosis. Read More ›

Fedratinib Improves Overall and Landmark Survival Rates in Patients Diagnosed with Myelofibrosis and Prior Ruxolitinib Treatment

ASH 2021 – Myelofibrosis: Wrap-up

Fedratinib, a JAK2 inhibitor, was recently approved to treat myelofibrosis in patients previously treated with ruxolitinib. Evidence suggests fedratinib may be a viable therapeutic option to improve survival in this patient population. Read More ›

Quality Improvement Program Identifies Disparities and Opportunities to Improve Delivery of Patient-Centered Care in Patients with Myeloproliferative Neoplasms

ASH 2021 – Myelofibrosis: Wrap-up

The rate of thrombus formation in patients with myelofibrosis is not well-defined. The intersection of IPSS score and JAK mutation may reliably indicate risk of vascular events in these patients. Read More ›

Pelabresib Monotherapy Demonstrates Clinical Activity in a Subset of Patients with Myelofibrosis with Limited Treatment Options and Poor Outcomes

ASH 2021 – Myelofibrosis: Wrap-up

Patients with myelofibrosis who are intolerant, refractory to, or ineligible for JAK inhibitor therapy such as ruxolitinib are generally difficult to treat and have poor prognoses. Evidence suggests pelabresib can safely and effectively improve clinical outcomes in this patient subset. Read More ›

Articles

Page 41 of 143